Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma

被引：13
|
作者：
Weber, Donna [1 ]
Knight, Robert [2 ]
Chen, Christine [3 ]
Spencer, Andrew [4 ]
Yu, Zhinuan [2 ]
Zeldis, Jerome [2 ]
Olesnyckyj, Marta [2 ]
Dimopoulos, Meletios [5 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Celgene Corp, Summit, NJ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[5] Univ Athens, Sch Med, GR-11527 Athens, Greece
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.412.412
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
412
引用
收藏
页码：128A / 128A
页数：1
相关论文
共 50 条
  • [41] Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, P. G.
    Trudel, S.
    Popat, R.
    Mateos, M-, V
    Vangsted, A. J.
    Ramasamy, K.
    Martinez-Lopez, J.
    Quach, H.
    Orlowski, R. Z.
    Arnao, M.
    Lonial, S.
    Karanes, C.
    Pawlyn, C.
    Kim, K.
    Oriol, A.
    Berdeja, J. G.
    Rodriguez Otero, P.
    Casas-Aviles, I
    Spirli, A.
    Poon, J.
    Li, S.
    Gong, J.
    Wong, L.
    Lamba, M.
    Pierce, D. W.
    Amatangelo, M.
    Peluso, T.
    Maciag, P.
    Katz, J.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (11): : 1009 - 1022
  • [42] Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
    Madhav V Dhodapkar
    Dennis L Cooper
    Nature Clinical Practice Oncology, 2008, 5 : 372 - 373
  • [43] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
  • [44] Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
    Dhodapkar, Madhav V.
    Cooper, Dennis L.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 372 - 373
  • [45] Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma.
    Wang, M.
    Knight, R.
    Dimopoulos, M.
    Siegel, D.
    Rajkumar, S. V.
    Facon, T.
    Yu, Z.
    Zeldis, J.
    Olesnyckyj, M.
    Weber, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 427S - 427S
  • [46] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [47] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
  • [48] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary E.
    Feng, Huaibao
    Brun, Nikolai Constantin
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [49] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
    Plesner, T.
    Arkenau, H. T.
    Lokhorst, H. M.
    Gimsing, P.
    Krejcik, J.
    Lemech, C.
    Minnema, M. C.
    Lassen, U.
    Ahmadi, T.
    Yeh, H.
    Guckert, M.
    Brun, N. C.
    Lisby, S.
    Basse, L.
    Palumbo, A.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 104 - 104
  • [50] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Kraftson, Stephanie
    Ross, Charles W.
    Harvey, Colleen
    Hideshima, Teru
    Sportelli, Peter
    Poradosu, Enrique
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480
12345